In high-risk populations RRSO has been shown to be very effective in reducing the risk of ovarian cancer [27,34], and in a recent study of more than 2500 women with germline pathogenic variant BRCA1/2 alleles who underwent RRSO, the 20-year cumulative incidence rate of HGSC was 1.5% for BRCA1 and 0.2% for BRCA2 [18]. Here, BRCA2 is linked to ovarian cancer.